Joel Baglole

Joel Baglole

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

Kezar Life Sciences (KZR) Stock Soars on Lupus Trial Results

Shares of Kezar Life Sciences are up an astounding 74% today after the biotechnology company reported positive results from its clinical trial regarding a treatment for the autoimmune disease Lupus.

AMZN Stock Will Have 2 Amazon Prime Day Catalysts in 2022

AMZN stock is getting a lift on news that Amazon will hold two Prime Day sales events this year as opposed to just one.

Ebang (EBON) Stock Rallies 20% After Nasdaq Delisting Warning

In an odd move, shares of Chinese blockchain company Ebang are rallying today after it said EBON stock could be delisted in the U.S.

Tencent (TCEHY) Stock Is Under Pressure as Prosus Trims Its Stake

Shares of TCEHY stock are down today on news that technology investor Prosus is trimming its stake in Tencent.

Why Is Epizyme (EPZM) Stock Up 75% Today?

Epizyme stock is up nearly 65% today on news that the biotechnology company is going to be acquired by French pharmaceutical concern Ipsen.